Aesculap Biologics
Aesculap Biologics is a U.S.-based, privately held biologics company developing NOVOCART 3D, a 3D biological scaffold in clinical trials for treating knee cartilage defects, serving the orthobiologics market from Breinigsville, PA.
- Company typePrivate
- Founded1867
- HeadquartersBreinigsville, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
Aesculap Biologics firmographics
Firmographics- Name
- Aesculap Biologics
- Website
- https://aesculapbiologics.com
- Company type
- Private
- Founded year
- 1867
- Headcount range
- 251–500 employees
- Short description
- Aesculap Biologics is a U.S.-based, privately held biologics company developing NOVOCART 3D, a 3D biological scaffold in clinical trials for treating knee cartilage defects, serving the orthobiologics market from Breinigsville, PA.
- Ownership category
- akta.pro rank
Aesculap Biologics industry classification
Industry- Product category
- Orthopedic Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
- akta.pro secondary industries
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
Keywords
Where Aesculap Biologics is headquartered
LocationHeadquarters
- HQ city
- Breinigsville
- HQ country
- United States
- HQ region
- North America
Markets served
Aesculap Biologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Aesculap Biologics product offering
Product offeringCore offering
Aesculap Biologics develops biological tissue repair therapies for orthopedic applications. Its lead program, NOVOCART 3D, is a tissue-engineered product in clinical trials intended for the treatment of knee cartilage defects, leveraging autologous chondrocyte transplantation technology.
Differentiator
Problem solved
Functional benefit
Products and services
- NOVOCART 3D
Companies that use Aesculap Biologics
Customer profileIdeal customer profiles1 record
Aesculap Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Aesculap Biologics competitors and assessment
Company assessmentDirect peers
- Anika Therapeutics: Anika is a specialty orthobiologics company developing hyaluronic-acid-based and regenerative therapies for joints and soft tissue, directly comparable to Aesculap Biologics' cartilage and tissue repair focus.
- Arthrex: Arthrex is a leading orthopedic device and biologics company with a broad cartilage repair portfolio (e.g., autologous chondrocyte implantation, osteochondral autograft systems), competing in the same surgeon channels and knee cartilage repair indications.
- Vericel Corporation: Vericel markets MACI, an autologous cultured chondrocyte implant for knee cartilage defects—the most direct competitive therapy to Aesculap Biologics' NOVOCART 3D, serving the same orthopedic surgeons and patient population.
Broad incumbents
- Stryker: Stryker's orthobiologics and sports medicine portfolio addresses cartilage and soft-tissue repair in the same end markets as Aesculap Biologics, though as part of a much broader orthopedic and surgical business.
- CONMED: CONMED operates in sports medicine and orthopedics with cartilage repair and biologic adjunct products, competing in the same surgical specialties as Aesculap Biologics.
- Smith & Nephew: Smith & Nephew is a diversified orthopedic incumbent with established cartilage repair and orthobiologics offerings (including legacy Osiris Therapeutics assets), overlapping Aesculap Biologics in regenerative knee solutions at greater scale.
- Zimmer Biomet: Zimmer Biomet is a major orthopedic incumbent with biologics offerings in cartilage, bone graft substitutes, and sports medicine, making it a broad competitor in the orthobiologics space Aesculap Biologics occupies.
Emerging players
- CartiHeal (Smith & Nephew): CartiHeal developed a cell-free, cartilage-implant technology for cartilage and osteochondral defects (acquired by Smith & Nephew); it represents an emerging technology pathway relevant to Aesculap Biologics' NOVOCART 3D development.
- Histogenics (now defunct / OCGN successor): Histogenics developed NeoCart, an autologous chondrocyte-based implant for knee cartilage repair—one of the closest historical comparables to NOVOCART 3D—and illustrates both the opportunity and execution risk in this niche.
Others
- B. Braun (parent ecosystem): B. Braun is the Aesculap parent organization providing surgical, orthopedic, and biologics infrastructure; understanding B. Braun's broader portfolio and capital allocation is essential context for Aesculap Biologics' strategic position.
Market position
Customer concentration
Aesculap Biologics social profiles
Digital presenceAesculap Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aesculap Biologics leadership team
Management profileNumber of profiles
Aesculap Biologics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aesculap Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aesculap Biologics
What does Aesculap Biologics do?
Aesculap Biologics develops biological tissue repair therapies for orthopedic applications. Its lead program, NOVOCART 3D, is a tissue-engineered product in clinical trials intended for the treatment of knee cartilage defects, leveraging autologous chondrocyte transplantation technology.
When was Aesculap Biologics founded?
Aesculap Biologics was founded in 1867. It employs 251 to 500 people.
Where is Aesculap Biologics based?
Aesculap Biologics is headquartered in Breinigsville, United States, in the North America region.
Who are Aesculap Biologics's main competitors?
Direct peers on record are Anika Therapeutics, Arthrex and Vericel Corporation. Broad incumbents are Stryker, CONMED, Smith & Nephew and Zimmer Biomet. Emerging players are CartiHeal (Smith & Nephew) and Histogenics (now defunct / OCGN successor). B. Braun (parent ecosystem) is listed as an others.
Does Aesculap Biologics have an API?
No public API is recorded for Aesculap Biologics.
What industry is Aesculap Biologics in?
Aesculap Biologics's product category is Orthopedic Biologics. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 325414 and its SIC code is 3842.